Project Grant R41EY039138
Award Date 7/15/26
Completion Date 5/31/27
Dollars Obligated $311K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Portland, OR 97220, USA
Similar Awards
- Federal Grant Award Summary Eye C Better Corp received a $315,825 Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), effective September 1, 2025, with a completion date of May 31, 2027. The project develops Photonic Intraocular Pressure (IOP) Biomonitoring (PIB), a non-invasive, non-contact tonometry method for measuring intraocular pressure in glaucoma patients. The technology uses sound wave-induced scleral oscillations detected through...
- Federal Grant Award Summary Fannin Partners LLC received a $600,032 Project Grant from the National Eye Institute under the Vision Research program (CFDA 93.867), effective September 1, 2025 through August 31, 2026. The award supports development of SCG3 raptamers—modified single-stranded DNA (ssDNA) aptamers—as a novel targeted therapy for wet age-related macular degeneration (AMD). Wet AMD, characterized by choroidal neovascularization (CNV), affects approximately 1.25 million Americans and...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded The Schepens Eye Research Institute Inc. a Project Grant totaling $545,948 under the Vision Research program (CFDA 93.867) to conduct basic and translational research on the role of reactive astrocytes in glaucoma pathogenesis. The research, which commenced April 1, 2026 and extends through March 31, 2030, will deliver scientific findings and data advancing understanding of non-neuronal cellular responses to ocular...
- Federal Grant Award Summary Proteris Biotech, Inc. received a $321,904 Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) effective August 1, 2025, through July 31, 2026. The award funds Phase I development of Clusterin (CLU), a novel therapeutic targeting epitheliopathy in dry eye disease. The company will conduct early-stage development activities at its Boston incubator facility, including non-Good Manufacturing Practice (GMP) stability...
- Federal Grant Award Summary The National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), awarded Kuria Therapeutics, Inc. a Project Grant of $799,730 effective September 30, 2025, with completion targeted for August 31, 2026. The grant supports Investigational New Drug (IND)-enabling studies for KTX-1161, a novel topical eye drop designed to protect corneal endothelial cells during cataract surgery and treat Fuchs' endothelial corneal dystrophy. The active ingredient,...
- Federal Grant Award Summary The National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), awarded The Leland Stanford Junior University a $1.51M Project Grant beginning September 1, 2025, through May 31, 2028, to develop endoplasmic reticulum (ER) stress chemical modulators as neuroprotectants for glaucoma treatment. The award supports research to optimize and validate small-molecule compounds—specifically CHOP (CCAAT/enhancer binding protein homologous protein) inhibitors...
- Federal Project Grant Award Summary Neovascularx, Inc. received a $305,321 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) for the clinical development and commercialization of topical ophthalmic products to treat neovascular age-related macular degeneration (NAMD). The award, obligated on September 30, 2025, with completion targeted for September 29, 2026, supports research and development of AMD101 (rifampicin), a repurposed compound designed...
- Federal Project Grant Award Summary The National Eye Institute (NEI) awarded The Ohio State University $413,478 on September 22, 2025, under the Vision Research program (CFDA 93.867) to develop and test a novel gene therapy delivery approach for inherited retinal disease (IRD). The project, titled "Insulin-Accelerated Surgical Approach to Pre-Retinal Gene Therapy," will extend through August 31, 2030. This research addresses significant limitations in existing adeno-associated virus...
- Federal Grant Award Summary Universal Adherence LLC received a $912,573 Project Grant from the National Eye Institute under the Vision Research program (CFDA 93.867) for the period of July 1, 2025 through June 30, 2027. The award supports the development and clinical testing of the iDrop Device (ID2), a smart electronic cap monitor designed to improve medication adherence for patients using prescribed eye drops. The device automatically tracks when patients remove eye drop bottle caps,...
- Federal Project Grant Award Summary The National Eye Institute (NEI) awarded The Schepens Eye Research Institute, Inc. a Project Grant of $881,797 under the Vision Research program (CFDA 93.867) effective May 1, 2026, with a completion date of April 30, 2028. The grant funds development of mini-USH2A gene therapy to treat Usher Syndrome Type 2A (USH2), the most common inherited condition causing combined hearing and vision loss worldwide. The research addresses a critical limitation in current...